Acticor Biotech

Acticor Biotech company information, Employees & Contact Information

Explore related pages

Related company profiles:

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Company Details

Employees
15
Founded
-
Address
Paris Santé Cochin, 27 Rue Du Faubourg Saint Jacques, Paris,75014,france
Phone
33970468640
Email
co****@****ech.com
Industry
Biotechnology
HQ
Paris
Looking for a particular Acticor Biotech employee's phone or email?

Acticor Biotech Questions

News

Acticor Biotech announces its liquidation proceedings - Yahoo Finance

Acticor Biotech announces its liquidation proceedings Yahoo Finance

Acticor halts phase 2/3 stroke trial for blood thinner over futility - Fierce Biotech

Acticor halts phase 2/3 stroke trial for blood thinner over futility Fierce Biotech

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment - Business Wire

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment Business Wire

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic - Labiotech.eu

The First Stroke Drug in Decades? French Biotech gets closer to the Clinic Labiotech.eu

Glenzocimab to be Trialled for Myocardial Infarction Treatment - Medscape

Glenzocimab to be Trialled for Myocardial Infarction Treatment Medscape

Acticor taps Merck’s MilliporeSigma for manufacturing services - BioPharma Dive

Acticor taps Merck’s MilliporeSigma for manufacturing services BioPharma Dive

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks - Taylor & Francis Online

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks Taylor & Francis Online

Stroke drug given priority medicine status by European Medicines Agency - Labiotech.eu

Stroke drug given priority medicine status by European Medicines Agency Labiotech.eu

New Therapeutics Options in Ischemic Stroke Pipeline as 40+ - GlobeNewswire

New Therapeutics Options in Ischemic Stroke Pipeline as 40+ GlobeNewswire

Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail

Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies The Globe and Mail

Emfret presents novel anticoagulant - European Biotechnology Magazine

Emfret presents novel anticoagulant European Biotechnology Magazine

China Firm Licenses French Stroke Drug for $70 Million - Caixin Global

China Firm Licenses French Stroke Drug for $70 Million Caixin Global

Full article: Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks - Taylor & Francis Online

Full article: Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks Taylor & Francis Online

FDA approves 6 MRI-safe ICDs and CRTs from Biotronik - Fierce Biotech

FDA approves 6 MRI-safe ICDs and CRTs from Biotronik Fierce Biotech

Six companies that have made their name in the cardiovascular space - Labiotech.eu

Six companies that have made their name in the cardiovascular space Labiotech.eu

Top Acticor Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant